REICH, K.; SIMPSON, E.; LANGLEY, R.; WARREN, R.; COSTANZO, A. .; SAEKI, H.; ALMGREN, P.; GJERUM, L.; CARLSSON, A.; GOODERHAM, M.; PINTER, A.; DE BRUIN WELLER, M.; BLAUVELT, A. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s143, 2023. DOI: 10.25251/skin.7.supp.143. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2027. Acesso em: 3 jul. 2024.